JMT & associates
CHARTERED ACCOUNTANTS
304/305, A-Wing, Winsway Complex, Old Police Lane, Opp. Andheri Railway Stn.,
Andheri (East), Mumbai - 400 069. • Tel.: 91 - 22 - 6236 5695 / 3502 7606
Website : www.jmta.co.in • E-mail : contact.jmta@gmail.com

Independent Auditor's Report

To
The Board of Directors
Neogen Chemicals Japan Corporation Limited
(Subsidary of Neogen Chemicals Limited, India)
Japan

Opinion

We have audited the accompanying financial statements of **Neogen Chemicals Japan Corporation Limited** ("the Company"), which comprises the Balance Sheet as at **31 March 2026**, the Statement of Profit and Loss (including Other Comprehensive Income), the Statement of Changes in Equity and the Statement of Cash Flows, for the year then ended, and notes to the financial statements, including material accounting policy information.

In our opinion, the aforesaid special purpose financial statements present fairly, in all material respects, the financial position of the Company as at March 31, 2026, and its financial performance including other comprehensive income, changes in equity and its cash flows for the year then ended in accordance with Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with relevant rules, solely for the purpose of consolidation with the financial statements of its holding company Neogen Chemicals Limited in India.

Basis for Opinion

We conducted our audit in accordance with the **Standards on Auditing (SAs)** as specified and issued by The Institute of Chartered Accountants of India as applicable to audits of financial statements prepared for special purposes. Our responsibilities under those Standards are further described in the **Auditor's Responsibilities** section of this report.

We are independent of the Company in accordance with the ethical requirements applicable to our audit, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Emphasis of Matter

Without modifying our opinion, we draw attention to the facts that the financial statements, which describes that these financial statements have been prepared in accordance with Indian Accounting Standards (Ind AS) solely for the purpose of reporting to the holding company in India for consolidation purposes and for the purpose of meeting the group reporting requirements of **Neogen Chemicals Limited** in connection with reporting under the Foreign Exchange Management (Overseas Investment) Directions, 2022 for the Annual Performance Report (APR), as described in the Financial Statements.

The Company is a Wholly owned Subsidiary of the Neogen Chemicals Ltd, India and the applicable laws of the host country do not require Mandatory Audit of the Company.

As a result, the Financial Statements may not be suitable for another purpose. Our opinion is not modified in respect of this matter.

Management's Responsibility for the Financial Statements

Management of the Company is responsible for the preparation and presentation of the Financial Statements in accordance with the applicable financial reporting framework this includes the design, implementation and maintenance of internal control relevant to the preparation of financial statements that are free from material misstatement, whether due to fraud or error. In preparing the financial statements, Management and the Board of Directors are also responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters relating to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so. The Board of Directors is also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Restriction on Use and Distribution

This report is intended solely for the information and use of **Neogen Chemicals Limited** and the Board of Directors of the Company for the purpose described above and should not be used, referred to, or distributed to any other party without our prior written consent.

For JMT & ASSOCIATES
Chartered Accountants
Firm's Registration No:104167W

Dhaval Gala
Membership No: 195948
UDIN: 26195948TIBSYR9391
Place: Mumbai
Date: 16.05.2026

NEOGEN CHEMICALS JAPAN CO. LTD.

NEOGEN CHEMICALS JAPAN CORPORATION LIMITED

Statement of Audited Financial Results for the Quarter and Year ended March 31, 2026

(₹ in Crore)

Sr. No.	Particulars	Standalone				
		For the Quarter Ended			For the Year ended	
		March 31, 2026	December 31, 2025	March 31, 2025	March 31, 2026	March 31, 2025
		Audited	Unaudited	Audited	Audited	Audited
I	Income					
	(a) Revenue from operations	1.09	0.23	-	1.98	-
	(b) Other income	-	-	-	-	-
	Total Income (net)	**1.09**	**0.23**	**-**	**1.98**	**-**
II	Expenses					
	(a) Cost of materials consumed	-	-	-	-	-
	(b) Changes in inventories of finished goods, work-in progress and stock-in-trade	-	-	-	-	-
	(c) Employee benefits expense	0.09	-	-	0.09	-
	(d) Finance costs	0.01	-	-	0.01	-
	(e) Depreciation and Amortization Expense	-	-	-	-	-
	(f) Other Expenses	0.93	0.17	0.01	1.70	0.01
	Total Expenses	**1.03**	**0.17**	**0.01**	**1.80**	**0.01**
III	**Profit / (loss) before taxes (I - II)**	**0.06**	**0.06**	**(0.01)**	**0.18**	**(0.01)**
IV	**Income Tax**					
	1. Current Tax	0.00	0.00	0.00	0.00	0.00
	2. Deferred Tax	-	-	-	-	-
V	**Profit for the period (III - IV)**	**0.06**	**0.06**	**(0.01)**	**0.18**	**(0.01)**
VI	**Other comprehensive income**					
	(i) Items that will not be reclassified to profit or loss	-	-	-	-	-
	(ii) Income tax related to items that will not be reclassified to profit or loss	-	-	-	-	-
	(iii) Items that will be reclassified to profit or loss				(0.00)	
	Total Other comprehensive (expense) / income, net of tax	**-**	**-**	**-**	**(0.00)**	**-**
VII	**Total comprehensive income for the period (V + VI)**	**0.06**	**0.06**	**(0.01)**	**0.18**	**(0.01)**

For and on behalf of board of directors of
Neogen Chemicals Japan Corporation Limited

Place : Thane, India
Date : May 16, 2026

Dr. Harin Kanani
Representative Director

NEOGEN CHEMICALS JAPAN CORPORATIONLIMITED

Statement of Audited Balance Sheet as at March 31, 2026

(₹ in Crore)

Particulars	As at March 31, 2026	As at March 31, 2025
ASSETS		
(1) Current Assets		
(a) Financial assets		
(i) Cash and cash equivalents	0.50	0.00
(ii) Other current financial assets	0.87	-
(b) Other current assets	0.19	-
Total Current Assets (I)	**1.56**	**0.00**
TOTAL ASSETS (I)	**1.56**	**0.00**
EQUITY AND LIABILITIES		
(1) Equity		
(a) Equity share capital	1.19	0.00
(b) Other equity	0.17	(0.01)
Total Equity (I)	**1.36**	**(0.01)**
(2) Current liabilities		
(a) Financial liabilities		
(i) Trade payables		
(a) Total outstanding dues of Micro-enterprises and small enterprises	-	-
(b) Total outstanding dues of other than micro-enterprises and small enterprises	0.20	0.01
(b) Current tax provisions (net)	0.00	0.00
Total Current liabilities (II)	**0.20**	**0.01**
TOTAL EQUITY AND LIABILITIES (I + II)	**1.56**	**0.00**

For and on behalf of board of directors of
Neogen Chemicals Japan Corporation Limited

Place : Thane, India
Date : May 16, 2026

Dr. Harin Kanani
Representative Director

NEOGEN CHEMICALS JAPAN CORPORATION LIMITED
Standalone Balance Sheet as at March 31, 2026

(₹ in Crore)

Particulars	Notes No.	As at March 31, 2026	As at March 31, 2025
ASSETS			
(1) Current Assets			
(a) Financial Assets		-	
(i) Cash and cash equivalents	3	0.50	0.00
(ii) Other financial assets	4	0.87	-
(b) Other current assets	5	0.19	-
Total Current Assets		**1.56**	**0.00**
Total Assets		**1.56**	**0.00**
EQUITY AND LIABILITIES			
(1) Equity			
(a) Equity share capital	6	1.19	0.00
(b) Other equity	7	0.17	(0.01)
Total Equity		**1.36**	**(0.01)**
(2) Liabilities			
(A) Current Liabilities			
(a) Financial Liabilities			
(i) Trade payables	8		
(a) total outstanding dues of micro and small enterprises		-	-
(b) total outstanding dues of creditors other than micro and small enterprises		0.20	0.01
(b) Current tax liabilities (net)	9	0.00	0.00
Total Liablities		**0.20**	**0.01**
Total Equity and Liabilities		**1.56**	**0.00**

Corporate information	**1**
Material accounting policies	**2**

The accompanying notes are an integral part of the financial statements

As per our report of even date attached
For JMT & Associates
Chartered Accountants
Firm Registration No. 104167W

Dhaval R Gala
Partner
Membership No. 195948
Place : Thane, India
Date : May 16, 2026

For and on behalf of board of directors of
Neogen Chemicals Japan Corporation Limited

Dr. Harin Kanani
Representative Director

NEOGEN CHEMICALS JAPAN CORPORATION LIMITED

Standalone Statement of Profit and Loss for the year ended March 31, 2026

(₹ in Crore)

Particulars	Note No.	For the year ended March 31, 2026	For the period ended March 31, 2025
I REVENUE			
Revenue from operations	10	1.98	-
TOTAL INCOME		**1.98**	**-**
II EXPENSES			
Cost of materials consumed		-	-
Changes in inventories of finished goods, work-in-progress and stock in		-	-
Employee benefits expense	11	0.09	-
Finance costs	12	0.01	-
Depreciation and amortisation expense		-	
Other expenses	13	1.70	0.01
TOTAL EXPENSES		**1.80**	**0.01**
III Profit before tax (I - II)		**0.18**	**(0.01)**
IV Tax Expenses			
- Current tax		0.00	0.00
- Deferred tax		-	-
V Profit for the year (III - IV)		**0.18**	**(0.01)**
VI Other Comprehensive Income			
(A) Items that will not be reclassified to profit or loss			
- Gain/(Loss) on remeasurement of defined benefit plans		-	-
- Income tax (expense)/ income relating to items that will not be reclassified to profit or loss		-	-
(B) Items that will be reclassified to profit or loss		(0.00)	-
Other Comprehensive Income for the year (net of tax)		**(0.00)**	**-**
VII Total Comprehensive Income for the year (V + VI)		**0.18**	**(0.01)**

Corporate information	**1**
Material accounting policies	**2**

The accompanying notes are an integral part of the financial statements

As per our report of even date attached
For JMT & Associates
Chartered Accountants
Firm Registration Np. 104167W

Dhaval R Gala
Partner
Membership No. 195948
Place : Thane, India
Date : May 16, 2026

For and on behalf of board of
Neogen Chemicals Japan Corporation Limited

Dr. Harin Kanani
Representative Director

Neogen Chemicals Japan Corporation Limited

Statement of Changes in Equity for the year ended March 31, 2026

(₹ in Crore)

A) Equity Share Capital	As at March 31, 2026	As at March 31, 2025
Balance at the beginning of the year	-	-
Changes in equity share capital during the year	1.19	0.00
Balance at the end of the year	1.19	0.00

B) Other Equity

For the year ended March 31, 2026

Description	Reserves and Surplus	Other comprehensive income	Total Other Equity
	Retained Earnings	Foreign Currency Translation Reserve	
Balance as at April 1, 2025	(0.01)		(0.01)
Profit for the year	0.18	(0.00)	0.18
At March 31, 2026	0.17	(0.00)	0.17

For the period ended March 31, 2025 Increase / (Decrease) in Trade Payables

Description	Reserves and Surplus	Other comprehensive income	Total Other Equity
	Retained Earnings	Foreign Currency Translation Reserve	
Balance as at April 1, 2024	-		-
Profit for the period	(0.01)		(0.01)
At March 31, 2025	(0.01)	-	(0.01)

As per our report of even date attached
For JMT & Associates
Chartered Accountants
Firm Registration No. 104167W

For and on behalf of board of directors of
Neogen Chemicals Japan Corporation Limited

Dhaval R Gala
Partner
Membership No. 195948
Place : Thane, India
Date : May 16, 2026

Dr. Harin Kanani
Representative Director

NEOGEN CHEMICALS JAPAN CORPORATION LIMITED

Standalone Cash Flow Statement for the year ended March 31, 2026

(₹ in Crore)

Particulars	For the year ended March 31, 2026	For the period ended March 31, 2025
A. Cash Flow from Operating Activities		
Net Profit before tax	0.18	(0.01)
Operating Profit before Working Capital changes	**0.18**	**(0.01)**
Adjustments for :		
(Increase) / Decrease in Current loans and advances and other current financial assets	(0.87)	-
(Increase) / Decrease in Other Current Assets	(0.19)	-
Finance Cost	0.01	-
Increase / (Decrease) in Trade Payables	0.19	0.01
Cash generated from operations	**(0.68)**	**(0.00)**
Income tax paid	(0.00)	-
Net Cash from Operating activities	**(0.68)**	**(0.00)**
B. Cash Flow from Investing Activities		
Net Cash used in Investing activities	**-**	**-**
C. Cash Flow from Financing Activities		
Proceeds from issue of equity instruments of the Company	1.19	0.00
Other Comprehensive Income for the year (net of tax)	(0.01)	-
Net Cash used in Financing activities	**1.18**	**0.00**
Net increase / (decrease) in cash and cash equivalents	**0.50**	**(0.00)**
Cash on Hand	0.0	-
Cash at Bank	-	-
Opening Cash and Cash Equivalents	**0.00**	**-**
Cash on Hand	0.00	0.0
Cash at Bank	0.50	-
Closing Cash and Cash Equivalents	**0.50**	**0.00**

As per our report of even date attached
For JMT & Associates
Chartered Accountants
Firm Registration No. 104167W

Dhāvāl R Gala
Partner
Membership No. 195948
Place : Thane, India
Date : May 16, 2026

For and on behalf of board of directors of
Neogen Chemicals Japan Corporation Limited

Dr. Harin Kanani
Representative Director

NEOGEN CHEMICALS JAPAN CORPORATION LIMITED

Accompanying notes to Standalone financial statements for the year ended March 31, 2026

1. **General corporate information**

   Neogen Chemicals Japan Corporation Limited ("the Company") is domiciled in Japan. Company has its registered office at Level 7, Wakamatsu Building, 3-3-6 Nihobashi Hon-Cho, Chou-Ku, Tokyo, Japan 103-0023, is in the business of Speciality Chemicals. It was incorporated on July 30, 2024. The holding company is Neogen Chemicals Limited.

2. **Summary of basis of preparation and presentation, key accounting estimates, assumptions and material accounting policies**

I. Basis of preparation and presentation

The accompanying financial statements have been prepared in accordance with generally accepted accounting principles.

- **Current versus non-current classification**

All assets and liabilities have been classified as per the Company's normal operating cycle. Based on the nature of the products and the time taken between acquisition of assets for processing and their realization in cash and cash equivalents, the Company has ascertained its operating cycle as twelve months for the purpose of the classification of assets and liabilities into current and non-current.

- **Basis of measurement**

The financial statements have been prepared on a historical cost basis, except for the following:
- certain financial assets and liabilities (including derivative instruments) that is measured at fair value;

- **Functional and presentation currency**

The financial statements have been prepared as per the functional and presentation currency of the Holding company i.e. in INR.

II. Key estimates and assumptions

While preparing financial statements in conformity with Japanese GAAP, the management has made certain estimates and assumptions that require subjective and complex judgments. These judgments affect the application of accounting policies and the reported amount of assets, liabilities, income and expenses, disclosure of contingent liabilities at the balance sheet date and the reported amount of income and expenses for the reporting period. Future events rarely develop exactly as forecasted and the best estimates require adjustments, as actual results may differ from these estimates under different assumptions or conditions. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized prospectively. Judgement, estimates and assumptions are required in particular for:

- **Recognition of deferred tax assets and liabilities**

  Deferred tax assets and liabilities are recognized for the future tax consequences of temporary differences between the carrying values of assets and liabilities and their respective tax bases. Deferred tax assets are recognized to the extent that it is probable that future taxable income will be available against which the deductible temporary differences.

- **Recognition and measurement of other provisions**

  The recognition and measurement of other provisions are based on the assessment of the probability of an outflow of resources, and on past experience and circumstances known at the balance sheet date. The actual outflow of resources at a future date may therefore, vary from the amount included in other provisions.

- **Discounting of long-term financial assets / liabilities**

  All financial assets / liabilities are required to be measured at fair value on initial recognition. In case of financial liabilities/assets which are required to subsequently be measured at amortised cost, interest is accrued using the effective interest method.

III. Material accounting policies

A. Revenue recognition and Other income

- **Sale of goods**

  The company manufactures and sells a range of products to various customers. In case of contracts with customers, revenue is recognised when the significant risk and rewards of ownership have been transferred to the customer, recovery of the consideration is probable, the associated costs and possible return of goods can be estimated reliably, there is no continuing management involvement with the goods to the degree usually associated with the ownership, and the amount of revenue can be measured reliably, regardless of when the payment is being made. Revenue is measured at the fair value of the consideration received or receivable. Revenue recognised in relation to these contracts in excess of billing is recognised as a Contract Asset. In remaining cases revenue is recognised over Company's performance does not create an asset with alternative use to the Company and the entity has an enforceable right to payment for performance completed till date. Accumulated experience is used to estimate and provide for the discounts and returns and revenue is only recognised to the extent that itis highly probable that a significant reversal will not occur. A refund liability (included in other current liabilities) is recognised for expected returns from the customer. Liability (included in other financial liabilities) is recognised for expected volume discounts payable to customers in relation to sales made until the end of the reporting period.

Amounts disclosed as revenue are net of returns, discounts, volume rebates and net of goods and service tax. Incentives on exports are recognised in books after due consideration of certainty of utilisation / receipt of such incentives.

- **Interest income**

Interest income is recognized on time proportion basis considering the amount outstanding and rate applicable. For all financial assets measured at amortized cost, interest income is recorded using the effective interest rate (EIR) i.e. the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to the net carrying amount of the financial assets. Interest income is included in other income in the Statement of Profit and Loss.

B. Foreign currency

- **Transaction and balances**

Transactions in foreign currencies are translated into the respective functional currencies of the Company at the exchange rates at the dates of the transactions or an average rate if the average rate approximates the actual rate at the date of the transaction. Foreign currency transactions are recorded on initial recognition in the functional currency, using the exchange rate at the date of the transaction. At each balance sheet date, foreign currency monetary items are reported using the closing exchange rate. Exchange differences that arise on settlement of monetary items or on reporting at each balance sheet date of the Company's monetary items at the closing rate are recognized as income and expenses in the period in which they arise. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rates at the dates of transactions. Non-monetary items that are measured at fair value in a foreign currency shall be translated using the exchange rates at the date when the fair value was measured.

Exchange differences are generally recognised in the Statement of Profit and Loss.

C. Employment Benefits

- **Short-term obligations**

All employee benefits payable wholly within twelve months of rendering services are classified as short term employee benefits. Short-term employee benefits are expensed as the related service is provided. A liability is recognized for the amount expected to be paid if the Company has a present legal or constructive obligationto pay this amount as a result of past service provided by the employee and the obligation can be estimated reliably. Short-term benefits such as salaries, wages, short-term compensation absences, etc., are determined on an undiscounted basis and recognized in the period in which the employee renders the related service.

- **Other long-term employee benefit obligations**

  Liability toward Long-term Compensated Absences is provided for on the basis of an actuarial valuation, using the Projected Unit Credit Method, as at the date of the Balance Sheet. Actuarial gains / losses comprising of experience adjustments and the effects of changes in actuarial assumptions are immediately recognised in the Statement of Profit and Loss. The obligations are presented as current liabilities in the balance sheet if the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period, regardless of when the actual settlement is expected to occur.

D. Borrowing costs

General and specific borrowing costs that are directly attributable to the acquisition, construction or production of a qualifying asset are capitalised during the period of time that is required to complete and prepare the asset for its intended use or sale. Qualifying assets are assets that necessarily take a substantial period of time to get ready for their intended use or sale. Other borrowing costs are expensed in the period in which they are incurred. Borrowing costs consist of interest and other costs that an entity incurs in connection with the borrowing of funds. Borrowing cost also includes exchange difference to the extent regarded as an adjustment to the borrowing costs.

E. Corporate Taxes

Corporate taxes, including corporation tax and local corporation tax, are recognized based on taxable income for the fiscal year. Current corporate tax liabilities are recorded at the amounts payable under the applicable Japanese tax laws.

F. Cash and cash equivalents

Cash and cash equivalent in the balance sheet comprise cash at banks and on hand, which are subject to an insignificant risk of changes in value.

G. Inventories

Inventories are carried in the balance sheet as follows:

a) **Raw materials, Packing materials and Stores & Spares:** Cost of purchases and other costs incurred in bringing the inventories to their present location and condition.
b) **Work-in-progress / project in progress:** At lower of cost of materials, plus appropriate manufacturing overheads and net realizable value.
c) **Finished Goods:** At lower of cost of materials, plus appropriate manufacturing overheads and net realizable value.

Net realizable value is the estimated selling price in the ordinary course of business, less the estimated costs of completion and the estimated costs necessary to make the sale. The net realizable value of work-in- progress is determined with reference to the selling prices of related finished products. Raw materials and other supplies held for use in the production of finished products are not written down below cost, except in cases where material prices have declined, and it is estimated that the cost of the finished products will exceed their net realizable value.

(₹ in Crore)

Note : 3 Cash and cash equivalents

Particulars	As at March 31, 2026	As at March 31, 2025
(i) Balances with banks :		
In current accounts	0.50	-
(ii) Cash on hand	0.00	0.00
Total	0.50	0.00

Note : 4 Other financial assets

Particulars	As at March 31, 2026	As at March 31, 2025
Receivable from Related Parties (Neogen Chemicals Limited)	0.87	-
Total	**0.87**	-

Note : 5 Other current assets

Particulars	As at March 31, 2026	As at March 31, 2025
Advance to Vendors	0.13	-
Other current assets	0.06	-
Total	**0.19**	-

Note : 6. Equity share capital

Particulars	As at March 31, 2026		As at March 31, 2025	
	No of shares	in INR	No of shares	in INR
Authorised capital				
Equity Shares of Yen 10/- each	20,01,000	-	10,000	-
Total	**20,01,000**	**0.00**	**10,000**	**0.00**
Issued, Subscribed and Fully Paid up				
Equity Shares of Yen 10/- each	20,00,100	1.19	100	0.00
Total	**20,00,100**	**1.19**	**100**	**0.00**

During the current period, the Company has issued 20,00,000 equity shares of Yen 10/- each to Neogen Chemicals Limited ("Holding Company") on April 30, 2025.

Note : 7. Other Equity

Particulars	As at March 31, 2026	As at March 31, 2025
Retained earnings	0.17	(0.01)
Foreign Currency Translation Reserve	(0.00)	
Total Other Equity	**0.17**	**(0.01)**

Note : 8. Trade Payables

Particulars	As at March 31, 2026	As at March 31, 2025
Trade Payable	0.20	0.01
Total	**0.20**	**0.01**

Note : 9. Current tax liability

Particulars	As at March 31, 2026	As at March 31, 2025
Provision for tax (Net of advance tax)	0.00	0.00
Total	**0.00**	**0.00**

(₹ in Crore)

Note : 10. Revenue from operations

Particulars	For the year ended March 31, 2026	For the period ended March 31, 2025
Service Charges	1.98	-
Total	1.98	-

Note : 11. Employee benefit expenses

Particulars	For the year ended March 31, 2026	For the period ended March 31, 2025
Salary expenses	0.09	-
Total	0.09	-

Note : 12. Finance Cost

Particulars	For the year ended March 31, 2026	For the period ended March 31, 2025
Bank Charges	0.01	-
Total	0.01	-

Note : 13. Other expenses

Particulars	For the year ended March 31, 2026	For the period ended March 31, 2025
Advertisement, Selling and Distribution Expenses	0.23	0.01
Consultancy Charges	0.90	-
Professional Fees	0.14	-
Travelling Exps	0.06	-
Commission Expenses	0.10	-
Office Rent	0.22	-
Telephone Expenses	0.01	-
Other Expenses	0.04	-
Total	1.70	0.01

As per our report of even date attached
For JMT & Associates
Chartered Accountants
Firm Registration No. 104167W

Dhaval R Gala
Partner
Membership No. 195948
Place : Thane, India
Date : May 16, 2026

For and on behalf of board of directors of
Neogen Chemicals Japan Corporation Limited

Dr. Harin Kanani
Representative Director